<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868010</url>
  </required_header>
  <id_info>
    <org_study_id>1R01HD055525</org_study_id>
    <secondary_id>NIH grant: 1 R01 HD055525-01A2</secondary_id>
    <nct_id>NCT00868010</nct_id>
  </id_info>
  <brief_title>Enhancing Rehabilitation After Stroke</brief_title>
  <acronym>Enhance</acronym>
  <official_title>Donepezil to Promote Functional Recovery Post-stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week, randomized, placebo controlled study to determine if donepezil (Aricept)
      treatment during rehabilitation after stroke improves functional recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stroke is a leading cause of disability in the US (Thom 2006). The total number of stroke
      survivors (currently estimated as 5.5 million Americans) will continue to increase as the
      population ages and as the medical management of acute stroke continues to improve. Given
      stroke's devastating impact on activities of daily living and the large numbers of Americans
      afflicted, improving acute medical rehabilitation outcomes after stroke is of great public
      health importance.

      Predictors of poor functional recovery post-stroke include impairments in cognition and
      motivation. Recent evidence indicates that acetylcholinesterase inhibitors may improve
      cognition and motivation; hence, their use post-stroke may lead to improved rehabilitation
      outcomes. Our group has demonstrated that use of the acetylcholinesterase inhibitor donepezil
      is associated with improved functional recovery in a pilot sample (n = 40) of elderly,
      cognitively impaired stroke survivors undergoing inpatient rehabilitation. Specifically, in
      this 12 week open-label study, those subjects receiving donepezil experienced a clinically
      meaningful 14 point greater improvement on the Functional Independence Measure (FIM) than an
      archival comparator group.

      Based on these promising pilot study results, we propose a 12-week randomized, double-blind,
      placebo-controlled trial (followed by a 12 week off-drug observation period) in order to test
      the efficacy of donepezil to promote post-stroke functional recovery in older, cognitively
      impaired stroke survivors undergoing inpatient rehabilitation. We will also use this
      randomized controlled trial to examine the drug's effect on cognition post-stroke;
      specifically, the drug's effect on those cognitive domains (attention/working memory,
      information psychomotor speed, and episodic memory) that are relevant to functional outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Independence Measure (FIM)</measure>
    <time_frame>Weekly/12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive Function (ImPACT battery used to assess attention - working memory continuum, information processing speed, and verbal and visual episodic memory.)</measure>
    <time_frame>Multiple time points over 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>1: donepezil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive treatment for 12 weeks on donepezil 10 mg (or 5 mg if unable to tolerate 10 mg). Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive treatment for 12 weeks with placebo pill. Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil</intervention_name>
    <description>5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.</description>
    <arm_group_label>1: donepezil</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Participants will receive a placebo pill for 12 weeks if randomized to this treatment.</description>
    <arm_group_label>2. placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. male or female;

          2. aged 18 or older;

          3. new ischemic stroke within the preceding 30 days; and

          4. admitted to the an inpatient facility of the UPMC Institute for Rehabilitation and
             Research for post-stroke rehabilitation.

        Exclusion Criteria:

          1. primary hemorrhagic stroke;

          2. current use of a cholinomimetic drug including tacrine, donepezil, galantamine, and
             rivastigmine;

          3. contraindication to AchEi therapy including bradycardia (&lt; 50 bpm), severe asthma or
             COPD requiring nebulized medication, and active upper GI bleed or untreated gastric
             ulcer;

          4. myocardial infarction, poorly controlled congestive heart failure, or coronary bypass
             surgery within the last 3 months;

          5. current required use of an anticholinergic medication (e.g., for bladder spasm);

          6. current aphasia severe enough to prevent valid neuropsychiatric assessment (e.g., a
             score &lt; 9 on the Token Test, part I and a score of &lt; 14 (or &lt;80% accuracy) on the
             repetition task of the Boston Diagnostic Aphasia Examination);

          7. current Major Depressive Episode AND HRSD &gt; 20;

          8. current active suicidal ideation, plan, or intent;

          9. current mania or hypomania;

         10. current psychosis;

         11. meeting DMS-IV TR alcohol or substance abuse or dependence criteria within the
             preceding 3 months;

         12. subject and/or family informant do not speak English;

         13. history of a progressive or unstable CNS disease (e.g., multiple sclerosis,
             Parkinson's disease, HIV with CNS involvement);

         14. medically unstable (determined by review of the subject's medical status with the
             treating (clinical) physician and by review of standard blood tests); and

         15. history of sensitivity to donepezil;

         16. for potential subjects without a pacemaker or implantable defibrillator, exclusion
             criteria will include (a) ECG evidence of second or third degree heart block ( b ) ECG
             evidence of a tri-fascicular block (LBBB and 1st degree AV Block; RBBB, left anterior
             or left posterior hemiblock, and 1st degree AV block) or ( c ) history of syncope
             within 1 year with a RBBB or a LBBB.

         17. For females of child-bearing age, current pregnancy, plan to become pregnant while on
             study drug, or refusal to avoid pregnancy while on study drug.

         18. For females of child-bearing age, current breast feeding.

         19. suicidal attempt in the past one year,

         20. an inpatient admission for depression in the past one year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen M Whyte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kara Kenton</last_name>
    <phone>412-246-5815</phone>
    <email>kentonkd@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hillside Rehabilitation Hospital</name>
      <address>
        <city>Warren</city>
        <state>Ohio</state>
        <zip>44484</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nancy Landgraff, PhD</last_name>
      <phone>330-941-2703</phone>
      <email>nlandgra@cc.ysu.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy Landgraff, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Kenton</last_name>
      <phone>412-246-5815</phone>
      <email>kentonkd@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Howard Aizenstein, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ellen M Whyte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meryl Butters, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ariel Gildengers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordan Karp, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oscar Lopez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sati Mazumdar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Munin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Reynolds, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Skidmore, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.strokeassociation.org</url>
    <description>American Stroke Association website provides general information regarding stroke and stroke prevention.</description>
  </link>
  <reference>
    <citation>Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006 Feb 14;113(6):e85-151. Epub 2006 Jan 11. Erratum in: Circulation. 2006 Apr 11;113(14):e696. Circulation. 2006 Dec 5;114(23):e630.</citation>
    <PMID>16407573</PMID>
  </reference>
  <reference>
    <citation>Whyte EM, Lenze EJ, Butters M, Skidmore E, Koenig K, Dew MA, Penrod L, Mulsant BH, Pollock BG, Cabacungan L, Reynolds CF 3rd, Munin MC. An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients. Cerebrovasc Dis. 2008;26(3):317-21. doi: 10.1159/000149580. Epub 2008 Jul 31.</citation>
    <PMID>18667813</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <last_update_submitted>March 4, 2013</last_update_submitted>
  <last_update_submitted_qc>March 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Ellen Whyte</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>donepezil</keyword>
  <keyword>recovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

